Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

This trial tests whether adding empagliflozin (an oral diabetes pill, often used in type 2 diabetes) to an automated insulin delivery system (a smart insulin pump) can improve blood sugar control in adults with type 1 diabetes who are not meeting their glucose goals. **You may be eligible if...** - You are 18 or older with a type 1 diabetes diagnosis of at least 1 year - You have been using a commercial automated insulin delivery (AID) system for at least 3 months - Your time spent in the target blood sugar range is less than 70% in the past 30 days - You agree to use effective birth control if of childbearing potential **You may NOT be eligible if...** - You are currently taking other glucose-lowering medications (like SGLT2 inhibitors or GLP-1 drugs) - You are pregnant, breastfeeding, or planning pregnancy - Your kidney function is severely reduced - You have had diabetic ketoacidosis (DKA) within 6 months or a severe low blood sugar episode requiring emergency care within 1 month - You use the Medtronic 670G or 770G system Talk to your doctor to see if this trial is right for you.